P186D

Name *

First Name Last Name
Email *
example@example.com
What best describes your title? *

MD RN/NP PA PharmD Professor Industry
Date of Birth:

Month Day Year
Date
NABP ID#
How many years have you been in practice?
How many patients do you typically see each month?
1. What were the results of the DIAN TU clinical trials? *

Solanezumab met its pre-specified endpoint and altered CSF Tau Solanezumab did not meet its pre-specified endpoint and did not alter CSF tau Gantenerumab did not meet its pre-specified endpoint but did lower CSF tau Gantenerumab met its pre-specified endpoint and did not lower CSF tau.
2. Please select the true statement about the contribution of genetic factors to the risk for late-onset AD: *

AD presents a monogenic inheritance with full penetrance AD has a polygenic inheritance typical of complex multifactorial disorders There is no genetic contribution to AD None of the above
3. True or False: Flortaucipir imaging tracks with clinical progression better than flortbetapir. *

True False
4. The most advanced clinical trials in Alzheimer’s disease are exploring which treatment modality? *

Inhibiting secretase inhibitors Promoting deep brain stimulation Anti-amyloid immunotherapy Increasing overall cerebral metabolism
5. Please select the most common symptoms of COVID in people with dementia: *

Cough Shortness of breath Fever Delirium Deterioration of the function status All of the above
6. Which neuropsychiatric symptoms deteriorated most in people with dementia during 5 weeks of lockdown? *

Irritability/liability Apathy Agitation Night-time behavioral disturbance Aberrant motor symptoms All of the above

7. How confident are you in your responses above? *

	1	2	3	4	5

1 is Not Confident, 5 is Extremely Confident

Complete the following Evaluation to receive your Certificate